Related references
Note: Only part of the references are listed.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review
Meghan E. Sise et al.
ONCOLOGIST (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Douglas B. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
Valerie Glutsch et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe-Elie Salem et al.
LANCET ONCOLOGY (2018)
Nivolumab-induced severe acute kidney injury with a long latent phase in a patient with non-small-cell lung cancer: A case report
Naohiro Uchida et al.
CLINICAL CASE REPORTS (2018)
Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency
Ramy M. Hanna et al.
CASE REPORTS IN NEPHROLOGY AND DIALYSIS (2018)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Acute interstitial nephritis related to immune checkpoint inhibitors
Julie Belliere et al.
BRITISH JOURNAL OF CANCER (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Nivolumab-associated acute glomerulonephritis: a case report and literature review
Kyungsuk Jung et al.
BMC NEPHROLOGY (2016)
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
G. Niklas Noren et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2013)
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
EP van Puijenbroek et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2002)
Share Paper
